Ratei Richard, Karawajew Leonid, Lacombe Francis, Jagoda Krystyna, Del Poeta Giovanni, Kraan Jaco, De Santiago Maria, Kappelmayer János, Björklund Elisabeth, Ludwig W-D, Gratama Jan, Orfao Alberto
HELIOS Klinikum Berlin, Charité-University Medicine Berlin, Germany.
Cytometry B Clin Cytom. 2006 Jan;70(1):1-9. doi: 10.1002/cyto.b.20075.
Multiparametric flow cytometry has become an indispensable but complex tool for the diagnosis of acute leukemias. Interpretation of immunophenotypic data within a six-parameter analytical space relies on the standardization and validation of the instrument, the reagents, and the procedure. To address whether or not residual normal lymphocytes, usually present within leukemic samples, can serve as internal quality control for fluorescence intensity, 116 leukemic and 35 normal samples were analyzed.
Eight laboratories participated in the study and recruited a total of 151 individuals including 29 patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), 77 with acute myeloid leukemia (AML), 10 with T-cell precursor acute lymphoblastic leukemia (T-ALL), and 35 normal bone marrow donors. Lymphocytes were gated according to the CD45hi/SSClo gating strategy, after which median fluorescence intensities (MFI) as well as percentages of positive cells (%positive) for CD19, CD22, CD7, and CD3 were recorded. Nonparametric statistics were used to compare variation within and between laboratories.
Normal lymphocytes within leukemic samples do not show substantial differences compared to lymphocytes from normal controls with respect to expression of CD19, CD22, CD7, and CD3. In particular, longitudinal control charts of MFI values for CD3 antigen provide useful information on analytical and instrument performance.
Residual normal lymphocytes can serve as internal quality control for studies addressing fluorescence intensity in the setting of immunophenotyping of acute leukemias.
多参数流式细胞术已成为诊断急性白血病不可或缺但又复杂的工具。在六参数分析空间内对免疫表型数据的解读依赖于仪器、试剂和操作程序的标准化及验证。为了探讨白血病样本中通常存在的残留正常淋巴细胞是否可作为荧光强度的内部质量控制,我们分析了116份白血病样本和35份正常样本。
八个实验室参与了该研究,共招募了151名个体,包括29例B细胞前体急性淋巴细胞白血病(BCP-ALL)患者、77例急性髓系白血病(AML)患者、10例T细胞前体急性淋巴细胞白血病(T-ALL)患者以及35名正常骨髓供者。根据CD45hi/SSClo门控策略对淋巴细胞进行设门,之后记录CD19、CD22、CD7和CD3的中位荧光强度(MFI)以及阳性细胞百分比(%阳性)。采用非参数统计方法比较各实验室内部及之间的差异。
白血病样本中的正常淋巴细胞在CD19、CD22、CD7和CD3的表达方面与正常对照的淋巴细胞相比无显著差异。特别是,CD3抗原MFI值的纵向控制图为分析和仪器性能提供了有用信息。
在急性白血病免疫表型分析中,残留正常淋巴细胞可作为研究荧光强度的内部质量控制。